Skip to main content

Peer Review reports

From: A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis

Original Submission
1 Sep 2022 Submitted Original manuscript
10 Oct 2022 Reviewed Reviewer Report - Xiangji Ying
10 Feb 2023 Reviewed Reviewer Report - Jeff Tornheim
14 Mar 2023 Author responded Author comments - Alexa Dierig
Resubmission - Version 2
14 Mar 2023 Submitted Manuscript version 2
19 Mar 2023 Reviewed Reviewer Report - Xiangji Ying
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
5 May 2023 Editorially accepted
6 Jun 2023 Article published 10.1186/s13063-023-07354-5

You can find further information about peer review here.

Back to article page